The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence
Abstract
BACKGROUND: In this study, the authors analyzed the efficacy and safety of gemtuzumab ozogamicin (GO) (Mylotarg®), an antibody‐targeted chemotherapy for CD33‐positive acute myeloid leukemia (AML). METHODS: Patients with CD33‐positive AML in first recurrence were entered in 3 open‐label, single‐arm, Phase II studies. Patients received monotherapy with GO 9 mg/m 2 as a 2‐hour intravenous infusion in 2 doses separated by 2 weeks. Patients were evaluated for remission, survival, and treatment‐emergent adverse events. RESULTS: Two hundred seventy‐seven patients (median age, 61 yrs) were treated with GO, and 71 patients (26%) achieved remission, which was defined as ≤ 5% blasts in the bone marrow without leukemic blasts in the peripheral blood, neutrophil recovery to ≥ 1500/μL, hemoglobin ≥ 9 g/dL, and independence from red blood cell and platelet transfusions. Complete remission (CR) with platelet recovery (≥ 100,000/μL) or without full platelet recovery (< 100,000/μL) (CRp) was observed in 35 patients (13%) and 36 patients (13%), respectively. The median recurrence‐free survival was 6.4 months for patients who achieved CR and 4.5 months for patients who achieved CRp. Although expected incidences of Grade 3 or 4 neutropenia (98%) and thrombocytopenia (99%) were observed, the incidence of Grade 3 or 4 sepsis (17%) and pneumonia (8%) was relatively low. Grade 3 or 4 hyperbilirubinemia and hepatic aspartate aminotransferase and alanine aminotransferase elevations were reported in 29%, 18%, and 9% of patients, respectively; 0.9% of patients who did not undergo prior or subsequent hematopoietic stem cell transplantation developed hepatic venoocclusive disease after GO treatment. CONCLUSIONS: When it was administered to patients with CD33‐positive AML in first recurrence, single‐agent GO induced a 26% remission rate with a generally acceptable safety profile. Cancer 2005. © 2005 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lowenberg, B., Downing, J. R., & Burnett, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909303411407 · Cited by 1,217
Sievers, E. L., Larson, R. A., Stadtmauer, E. A., Estey, E., Löwenberg, B., Dombret, H., Karanes, C., Theobald, M., Bennett, J. M., Sherman, M. L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3244 · Cited by 899
Self-citationLeith, C. P., Kopecky, K. J., Godwin, J., McConnell, T., Slovak, M. L., Chen, I.-M., Head, D. R., Appelbaum, F. R., & Willman, C. L. (1997) · Blood · doi:10.1182/blood.v89.9.3323 · Cited by 859
Self-citationApproval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross, P. F., Beitz, J. G., Chen, G., Chen, X., Duffy, E. J., Kieffer, L. V., Roy, S., Sridhara, R. N., Rahman, A., Williams, G., et al. (2001) · PubMed · Cited by 855
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Hamann, P. R., Hinman, L. M., Hollander, I., Beyer, C. F., Lindh, D., Holcomb, R., Hallett, W., Tsou, H.-R., Upeslacis, J., Shochat, D., et al. (2002) · Bioconjugate Chemistry · doi:10.1021/bc010021y · Cited by 594
Self-citationSievers, E. L., Appelbaum, F. R., Spielberger, R. T., Forman, S. J., Flowers, D., Smith, F. O., Shannon-Dorcy, K., Berger, M. S., & Bernstein, I. D. (1999) · Blood · doi:10.1182/blood.v93.11.3678 · Cited by 512
Self-citationHematopoietic Cell Transplantation
Bitran, J. (2000) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.283.2.262-a · Cited by 508
A randomized study of high-dose cytarabine in induction in acute myeloid leukemia [see comments]
Bishop, J., Matthews, J., Young, G., Szer, J., Gillett, A., Joshua, D., Bradstock, K., Enno, A., Wolf, M., & Fox, R. (1996) · Blood · doi:10.1182/blood.v87.5.1710.1710 · Cited by 458
Weick, J., Kopecky, K., Appelbaum, F., Head, D., Kingsbury, L., Balcerzak, S., Bickers, J., Hynes, H., Welborn, J., Simon, Sr., et al. (1996) · Blood · doi:10.1182/blood.v88.8.2841.bloodjournal8882841 · Cited by 411
Self-citation
Cited by
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C., & Thun, M. J. (2006) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.2.106 · Cited by 5,314
Jordan, C. T., Guzman, M. L., & Noble, M. (2006) · New England Journal of Medicine · doi:10.1056/nejmra061808 · Cited by 1,702
Antibody-Drug Conjugates in Cancer Therapy
Sievers, E. L., & Senter, P. D. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-050311-201823 · Cited by 770
Self-citationPetersdorf, S. H., Kopecky, K. J., Slovak, M., Willman, C., Nevill, T., Brandwein, J., Larson, R. A., Erba, H. P., Stiff, P. J., Stuart, R. K., et al. (2013) · Blood · doi:10.1182/blood-2013-01-466706 · Cited by 638
Self-citationSchmid, C., Labopin, M., Nagler, A., Bornhäuser, M., Finke, J., Fassas, A., Volin, L., Gürman, G., Maertens, J., Bordigoni, P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6053 · Cited by 516
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023) · Cancers · doi:10.3390/cancers15030713 · Cited by 441
Antibody-Drug Conjugates for Cancer Therapy
Carter, P. J., & Senter, P. D. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e318172d704 · Cited by 429
Kenderian, S. S., Ruella, M., Shestova, O., Klichinsky, M., Aikawa, V, Morrissette, J. J. D., Scholler, J., Song, D., Porter, D. L., Carroll, M., et al. (2015) · Leukemia · doi:10.1038/leu.2015.52 · Cited by 426
Wang, Q.-S., Wang, Y., Lv, H.-Y., Han, Q.-W., Fan, H., Guo, B., Wang, L.-L., & Han, W.-D. (2015) · Molecular Therapy · doi:10.1038/mt.2014.164 · Cited by 418
Burnett, A. K., Russell, N. H., Hills, R. K., Kell, J., Freeman, S., Kjeldsen, L., Hunter, A. E., Yin, J., Craddock, C. F., Dufva, I. H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.2964 · Cited by 409
Potent antibody drug conjugates for cancer therapy
Senter, P. D. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.03.023 · Cited by 401
Acute myeloid leukemia: 2019 update on risk‐stratification and management
Estey, E. H. (2018) · American Journal of Hematology · doi:10.1002/ajh.25214 · Cited by 371
Self-citationRicart, A. D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0486 · Cited by 332
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy
Walter, R. B., Appelbaum, F. R., Estey, E. H., & Bernstein, I. D. (2012) · Blood · doi:10.1182/blood-2011-11-325050 · Cited by 321
Self-citationRosenblat, T. L., McDevitt, M. R., Mulford, D. A., Pandit-Taskar, N., Divgi, C. R., Panageas, K. S., Heaney, M. L., Chanel, S., Morgenstern, A., Sgouros, G., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0382 · Cited by 271
Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery
Dou, H., Destache, C. J., Morehead, J. R., Mosley, R. L., Boska, M. D., Kingsley, J., Gorantla, S., Poluektova, L., Nelson, J. A., Chaubal, M., et al. (2006) · Blood · doi:10.1182/blood-2006-03-012534 · Cited by 253
A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers
Liu, K., Li, M., Li, Y., Li, Y., Chen, Z., Tang, Y., Yang, M., Deng, G., & Liu, H. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01963-7 · Cited by 196
“Following positive outcomes from three early clinical trials, the FDA granted approval of GO in 2000, specifically for the treat-ment of patients with CD33-positive AML aged over 60 who were ineligible for cytotoxic chemotherapy [10].”
BackgroundWang, Y., Fan, S., Xiao, D., Xie, F., Li, W., Zhong, W., & Zhou, X. (2019) · Cancers · doi:10.3390/cancers11070957 · Cited by 50
Monoclonal Antibodies: A Prospective and Retrospective View
Sivaccumar, J., Sandomenico, A., Vitagliano, L., & Ruvo, M. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867327666200219142231 · Cited by 14
Metadata
- Authors
- Larson, R. A., Sievers, E. L., Stadtmauer, E. A., Löwenberg, B., Estey, E. H., Dombret, H., Theobald, M., Voliotis, D., Bennett, J. M., Richie, M., Leopold, L. H., Berger, M. S., Sherman, M. L., Loken, M. R., van Dongen, J. J. M., Bernstein, I. D., Appelbaum, F. R., & Mylotarg Study Group
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2005-09-17
- Volume
- 104
- Issue
- 7
- Pages
- 1442-1452
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2065406906
- Cited by
- 460
- References
- 24
- FWCI
- 14.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.